Carisma Therapeutics, Inc. (CARM)

Carisma Therapeutics, Inc. (CARM) — VMCI valuation read

Composite valuation read on CARM: VMCI 45/100 against a Healthcare sector median of 50. The 5-point below-median print is the headline number for Carisma Therapeutics, Inc., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for CARM: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on CARM: CARM trades at 27.0x earnings, 50% above the Healthcare median of 18.0x; ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp; net debt to EBITDA of -0.5x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

CARM fell 3.8% over the trailing 7 days, with a +4.6% read on a 30-day basis.